Europe - Frankfurt Stock Exchange - FRA:ILM1 - DE000A1MMCC8 - Common Stock
The current stock price of ILM1.DE is 14.94 EUR. In the past month the price increased by 4.53%. In the past year, price increased by 17.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AXNA.DE | AMPLIFON SPA | 26.75 | 3.21B | ||
| AMP.MI | AMPLIFON SPA | 25.29 | 3.03B | ||
| FAGR.BR | FAGRON | 18.59 | 1.60B | ||
| UPR.I | UNIPHAR PLC | 16.36 | 934.45M | ||
| BLC.PA | BASTIDE LE CONFORT MEDICAL | 351.43 | 181.30M | ||
| VMED.DE | VIROMED MEDICAL AG | N/A | 89.10M |
Medios AG is a holding company, which engages in the provision of pharmaceutical drugs. The company is headquartered in Berlin, Berlin and currently employs 999 full-time employees. The firm covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. The company operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.
MEDIOS AG
Heidestrasse 9
Berlin BERLIN DE
Employees: 999
Phone: 4930232566800
Medios AG is a holding company, which engages in the provision of pharmaceutical drugs. The company is headquartered in Berlin, Berlin and currently employs 999 full-time employees. The firm covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. The company operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.
The current stock price of ILM1.DE is 14.94 EUR. The price decreased by -1.97% in the last trading session.
ILM1.DE does not pay a dividend.
ILM1.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
ILM1.DE stock is listed on the Frankfurt Stock Exchange exchange.
12 analysts have analysed ILM1.DE and the average price target is 24.14 EUR. This implies a price increase of 61.58% is expected in the next year compared to the current price of 14.94.
You can find the ownership structure of MEDIOS AG (ILM1.DE) on the Ownership tab.
ChartMill assigns a technical rating of 9 / 10 to ILM1.DE. When comparing the yearly performance of all stocks, ILM1.DE is one of the better performing stocks in the market, outperforming 78.68% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ILM1.DE. ILM1.DE has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months ILM1.DE reported a non-GAAP Earnings per Share(EPS) of 0.87. The EPS increased by 63.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.09% | ||
| ROA | 2.34% | ||
| ROE | 4.25% | ||
| Debt/Equity | 0.32 |
12 analysts have analysed ILM1.DE and the average price target is 24.14 EUR. This implies a price increase of 61.58% is expected in the next year compared to the current price of 14.94.
For the next year, analysts expect an EPS growth of 4.73% and a revenue growth 8.28% for ILM1.DE